Vistagen Therapeutics (MEX:VTGN) 12-1 Month Momentum %: N/A% (As of Aug. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:VTGN Vistagen Therapeutics Inc MEX:VTGN
16 GF Score
Price MXN10.65
! 3 Warning Signs
View Full Analysis

What is Vistagen Therapeutics 12-1 Month Momentum %?

Vistagen Therapeutics MEX:VTGN 16 12-1 Month Momentum % is N/A% as of Aug. 25, 2026. GuruFocus rates MEX:VTGN with a GF Score™ of 16/100. The stock has 3 warning signs investors should review. Among 1,359 Biotechnology companies, Vistagen Therapeutics ranks worse than 96.91% on this metric.

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-25), Vistagen Therapeutics's 12-1 Month Momentum % is N/A%.

The industry rank for Vistagen Therapeutics's 12-1 Month Momentum % or its related term are showing as below:

MEX:VTGN's 12-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -22.2
* Ranked among companies with meaningful 12-1 Month Momentum % only.

Vistagen Therapeutics  (MEX:VTGN) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Vistagen Therapeutics 12-1 Month Momentum % Related Terms

MEX:VTGN
16GF Score
Vistagen Therapeutics Inc MEX:VTGN
12-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vistagen Therapeutics  (MEX:VTGN) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 12-1 Month Momentum % →
What does a 12-1 Month Momentum % of N/A% mean?
Vistagen Therapeutics (MEX:VTGN) has a 12-1 Month Momentum % of N/A% as of Aug. 25, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Vistagen Therapeutics and its competitors. According to the industry distribution chart, Vistagen Therapeutics ranks #1317 out of 1359 companies in the Biotechnology industry, placing it in the top 96.9%.
Is Vistagen Therapeutics' 12-1 Month Momentum % too high?
Vistagen Therapeutics' current 12-1 Month Momentum % is N/A%. Based on the distribution chart, Vistagen Therapeutics ranks #1317 out of 1359 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vistagen Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Vistagen Therapeutics' 12-1 Month Momentum % compare to ASBP and CRIS?
According to the Biotechnology industry distribution chart, Vistagen Therapeutics ranks #1317 out of 1359 companies for 12-1 Month Momentum %. This places Vistagen Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Vistagen Therapeutics and its competitors. Vistagen Therapeutics's current 12-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistagen Therapeutics stock overvalued right now?
Vistagen Therapeutics (MEX:VTGN) has a current 12-1 Month Momentum % of N/A%. The current 12-1 Month Momentum % is N/A%. Vistagen Therapeutics' overall GF Score™ is 16/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Vistagen Therapeutics (MEX:VTGN), the current 12-1 Month Momentum % is N/A% as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vistagen Therapeutics Business Description

Other Exchanges VTGN:USA
Address 343 Allerton Avenue, South San Francisco, CA, USA, 94080
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
16GF Score

Get the complete analysis for MEX:VTGN

12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN10.65
Price